WT1 antigen peptide conjugate vaccine
View Patent ↗A compound represented by the formula (1): wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2): wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
1. A compound selected from the group consisting of
and
wherein the bond between CR is a bond between the carbonyl group of C and the N-terminal amino group of R, and the bond between C and C is a disulfide bond,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound has formula (4):
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound has formula (5):
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRK (SEQ ID NO: 22).
8. The pharmaceutical composition of claim 6 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 24).
9. The pharmaceutical composition of claim 6 , further comprising a peptide consisting of an amino acid sequence:
CWAPVLDFAPPGASAYGSL (SEQ ID NO: 242).
10. The pharmaceutical composition of claim 6 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSLC (SEQ ID NO: 243).
11. The pharmaceutical composition of claim 6 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSL (SEQ ID NO: 244).
12. The pharmaceutical composition of claim 4 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRK (SEQ ID NO: 22).
13. The pharmaceutical composition of claim 5 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRK (SEQ ID NO: 22).
14. The pharmaceutical composition of claim 4 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 24).
15. The pharmaceutical composition of claim 5 , further comprising a peptide consisting of an amino acid sequence:
CNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 24).
16. The pharmaceutical composition of claim 4 , further comprising a peptide consisting of an amino acid sequence:
CWAPVLDFAPPGASAYGSL (SEQ ID NO: 242).
17. The pharmaceutical composition of claim 5 , further comprising a peptide consisting of an amino acid sequence:
CWAPVLDFAPPGASAYGSL (SEQ ID NO: 242).
18. The pharmaceutical composition of claim 4 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSLC (SEQ ID NO: 243).
19. The pharmaceutical composition of claim 5 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSLC (SEQ ID NO: 243).
20. The pharmaceutical composition of claim 4 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSL (SEQ ID NO: 244).
21. The pharmaceutical composition of claim 5 , further comprising a peptide consisting of an amino acid sequence:
WAPVLDFAPPGASAYGSL (SEQ ID NO: 244).